Dr. Abhishek Kalla, MD

Dr. Kalla practices at Ascension Saint Agnes Hospital in Baltimore, Maryland, part of Ascension Health Alliance.

Dr. Kalla's NPI, 1508085887, was assigned on April 24, 2007. Dr. Kalla graduated from St Christopher's College of Medicine in 2006. Dr. Kalla holds Maryland license D79335.

Dr. Kalla's primary practice is Ascension Saint Agnes Hospital, at 900 Caton Avenue, Baltimore, MD 21229 in Baltimore City. The practice phone is (410) 368-6000.

Dr. Kalla's primary practice is Ascension Saint Agnes Hospital in Baltimore, Maryland, part of Ascension Health Alliance. The medical group on file is Integrated Specialists Group. Dmand AI also links Dr. Kalla to 1 more hospice, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalla practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kalla's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kalla is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kalla's licenses on file in 4 states: Maryland, Virginia, District of Columbia and Georgia.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and lung cancer among the conditions Dr. Kalla treats.

CMS data shows 909 Medicare services from Dr. Kalla across 7 procedure codes in 2024, for 342 Medicare patients. Medicare paid $84,365 for them.

CMS counts 342 Medicare patients who saw Dr. Kalla in 2024. The largest group is 75 to 84, with 137 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalla's median patient age at 69, with 52% women.

In 2024, Dr. Kalla wrote 861 Medicare Part D claims for 106 patients. 72% of them were for generic drugs. CMS names the drug for 714 of them, across 22 drugs with 11 or more claims each, at $1,847,342 in total drug cost. In 2023, CMS named 591 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Kalla for performance year 2024, reported as part of a group. Dr. Kalla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalla as offering telehealth.

Dmand AI links 9 papers to Dr. Kalla, published from 2018 to 2024. 2023 was the busiest year, with 3. Dr. Kalla has published most often in Cureus. Dr. Kalla's most frequent co-authors are Samaj Adhikari, MD, Abbas K. Ali, MD and Mahmoud Ayed Shaker Amr, MD.

CMS Open Payments shows 43 general payments to Dr. Kalla from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 39% of the total. Celgene Corporation paid the most, $5,846.

Dr. Kalla graduated from St Christopher's College of Medicine in 2006.

Dr. Kalla is in network with 17 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and CareFirst BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.